Get the Stockscreener App
20.20
3.40%
-0.71
After Hours:
20.20
Structure Therapeutics Inc Adr stock is traded at $20.20, with a volume of 892.25K.
It is down -3.40% in the last 24 hours and up +0.40% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$20.91
Open:
$20.91
24h Volume:
892.25K
Relative Volume:
0.98
Market Cap:
$1.16B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-9.0991
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
-3.16%
1M Performance:
+0.40%
6M Performance:
-4.04%
1Y Performance:
-50.54%
1-Day Range:
$20.14
$21.26
1-Week Range:
$20.14
$21.49
52-Week Range:
$13.22
$45.37
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
20.20 | 1.20B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.21 | 101.15B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.14 | 61.07B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.59 | 59.35B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.83 | 46.29B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.27 | 35.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Exome Asset Management LLC Decreases Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Equities Analysts Set Expectations for GPCR Q3 Earnings - MarketBeat
Cubist Systematic Strategies LLC Has $949,000 Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Lifesci Capital to Strong-Buy Rating - MarketBeat
This Under-the-Radar Healthcare Stock Could Soar in 2026 - The Globe and Mail
Zimmer Partners LP Acquires 43,876 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Layoff Tracker: Merck To Cut 125 Employees as It Ends UK R&D Work - BioSpace
Trexquant Investment LP Grows Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets - TipRanks
Structure Therapeutics stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
First-Ever Structural Analysis: Armata's Therapeutic Phage Pa223 Shows Promise for Antibiotic-Resistant Infections - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Trading Up 5.3%Time to Buy? - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Vestal Point Capital LP - MarketBeat
Point72 Europe London LLP Purchases 59,277 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Novan (NOVN) - The Globe and Mail
Jump Financial LLC Buys New Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
DAFNA Capital Management LLC Has $1.02 Million Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Tema Etfs LLC Lowers Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Obesity Drug Developer Structure Therapeutics to Present at Major Healthcare Conferences in September - Stock Titan
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences - The Globe and Mail
Invesco Ltd. Boosts Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: OnKure Therapeutics (OKUR), Inventiva (IVA) - The Globe and Mail
American Century Companies Inc. Has $8.83 Million Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Microsoft Corporation $MSFT Stock Holdings Cut by Alpine Woods Capital Investors LLC - Defense World
Analyzing Leap Technology (OTCMKTS:LPTC) and Molina Healthcare (NYSE:MOH) - Defense World
Promotora de Informaciones (OTCMKTS:PRISY) Trading 20.3% Higher – Still a Buy? - Defense World
ArcelorMittal South Africa (OTCMKTS:AMSIY) Trading Down 23.2% – What’s Next? - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Buy" from Analysts - MarketBeat
Enterprise Group (TSE:E) Given a C$2.42 Price Target at Fundamental Research - Defense World
Culp (CULP) to Release Quarterly Earnings on Wednesday - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% HigherHere's Why - MarketBeat
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - Bergen Record
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (TARA), Annexon Biosciences (ANNX) and Agilent (A) - The Globe and Mail
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform - MarketScreener
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors - The Motley Fool
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity - PR Newswire
Structure Therapeutics’ SWOT analysis: oral GLP-1 stock faces pivotal phase - Investing.com
SEED Therapeutics Named Finalist for 2025 Prix Galien USA 'Best Start-Up” Award - The Manila Times
Can Structure Therapeutics’ (GPCR) Aggressive Funding Moves Accelerate Its Obesity Drug Ambitions? - Yahoo Finance
ABSSSI Pipeline 2025: Detailed Clinical Trials - openPR.com
Up 23% to 132%, There's Still Time to Buy These 3 Stocks - The Globe and Mail
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
FY2025 EPS Estimates for GPCR Lowered by Cantor Fitzgerald - Defense World
William Blair Has Bearish Forecast for GPCR Q3 Earnings - Defense World
FY2025 EPS Estimates for GPCR Decreased by HC Wainwright - Defense World
Leerink Partnrs Has Negative Forecast for GPCR Q3 Earnings - Defense World
Leerink Partnrs Issues Negative Outlook for GPCR Earnings - Defense World
PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating - TipRanks
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.33%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):